Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy to Insulin Pumps for Type 1 Diabetes: A Systematic Review and Meta-Analysis
Pooled result · Time-in-rangeResult — go to the resultMD 11.89 % 95% CI 9.38–14.40Authors' conclusion
SGLT2 inhibitors combined with insulin pump therapy improve glycemic outcomes in T1D but elevate DKA risk, underscoring the need for individualized treatment, careful dosing, and vigilant monitoring.
Study context
- Population
- T1D using insulin pumps; RCTs published up to September 18, 2025
- Participants
- 2,916 participants17 trials
- Comparison
- SGLT2i add-on to insulin pump vs insulin pump alone
- Outcome
- Time-in-range
Pooled result
As reported in the abstract
MD
11.89 %
95% CI 9.38–14.40
P < 0.001
SGLT2i + insulin pumpvs Insulin pump alone
MD 11.89 % (95% CI 9.38–14.40); P < 0.001
Further pooled results
| Outcome | MD (%) (95% CI) | |
|---|---|---|
| HbA1cSGLT2i + insulin pumpvs Insulin pump aloneDecreased significantly | −0.30 (−0.41 to −0.20) | |
| −0.6−0.4−0.200.2Difference, % (linear scale) |
Time-in-range by SGLT2i dose
- Comparable increase in time-in-range, low-dose SGLT2i
- 11.89%
- Comparable increase in time-in-range, high-dose SGLT2i
- 12.22%
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| DKASGLT2i + insulin pumpvs Insulin pump alone | 3.33 (2.10–5.27) | |
| 0.20.5125Odds ratio (log scale) |
- Diabetic ketoacidosis (DKA) — NNH
- 27
DKA by SGLT2i dose
- Similar DKA risk, low-dose SGLT2i (OR)
- 2.90
- Similar DKA risk, high-dose SGLT2i (OR)
- 3.66
Original publication
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy to Insulin Pumps for Type 1 Diabetes: A Systematic Review and Meta-Analysis. Endocr Pract. Published 30 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →